Float Short %

6.41

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

0.99

EPS Last/This Y

-2.44

EPS This/Next Y

1.23

Price

69.62

Target Price

92.75

Analyst Recom

Performance Q

25.62

Relative Volume

1.88

Beta

1.2

Ticker: MRUS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	MRUS	67.27	0.72	0.17	23711
2025-08-18	MRUS	65.96	0.63	0.29	20660
2025-08-19	MRUS	63.35	0.63	0.33	20781
2025-08-20	MRUS	64.45	0.63	0.31	20822
2025-08-21	MRUS	66.67	0.63	0.66	20838
2025-08-22	MRUS	67.46	0.63	0.03	20860
2025-08-25	MRUS	66.1	0.63	0.17	20870
2025-08-26	MRUS	66.85	0.62	0.38	20932
2025-08-27	MRUS	67.23	0.63	0.01	20971
2025-08-28	MRUS	66.15	0.62	0.05	21121
2025-08-29	MRUS	65.76	0.64	150.20	20862
2025-09-02	MRUS	66.34	0.61	0.00	20467
2025-09-03	MRUS	66.61	0.60	0.00	20506
2025-09-04	MRUS	66.17	0.60	0.46	20620
2025-09-05	MRUS	67.11	0.61	0.14	21246
2025-09-08	MRUS	67.2	0.61	0.77	21120
2025-09-09	MRUS	68.55	0.64	0.89	25859
2025-09-10	MRUS	67.13	0.66	0.03	28018
2025-09-11	MRUS	69.82	0.67	1.61	30266
2025-09-12	MRUS	69.26	0.65	0.08	28231
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	MRUS	67.25	8.8	-13.7	-6.00
2025-08-18	MRUS	65.96	8.8	-3.8	-6.00
2025-08-19	MRUS	63.65	8.8	3.2	-6.00
2025-08-20	MRUS	64.43	8.8	-17.1	-6.00
2025-08-21	MRUS	66.67	8.8	-26.5	-6.00
2025-08-22	MRUS	67.54	8.8	-17.5	-6.00
2025-08-25	MRUS	65.79	8.8	-1.2	-6.00
2025-08-26	MRUS	66.86	8.8	-19.0	-6.00
2025-08-28	MRUS	66.10	8.8	-4.4	-6.00
2025-08-29	MRUS	65.83	8.8	-10.1	-6.00
2025-09-02	MRUS	66.31	9.7	-14.8	-5.79
2025-09-03	MRUS	66.65	9.7	-21.5	-5.79
2025-09-04	MRUS	66.20	9.7	-16.5	-5.79
2025-09-05	MRUS	67.47	9.7	-27.3	-5.79
2025-09-08	MRUS	67.19	9.7	-17.5	-5.79
2025-09-09	MRUS	68.60	9.7	-28.2	-5.79
2025-09-10	MRUS	67.14	9.7	-10.5	-5.79
2025-09-11	MRUS	69.80	9.7	-36.3	-5.79
2025-09-12	MRUS	69.62	9.7	-18.2	-5.79
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	MRUS	-1.03	-0.80	6.97
2025-08-18	MRUS	-1.03	-0.06	6.96
2025-08-19	MRUS	-1.04	-0.06	6.96
2025-08-20	MRUS	-1.04	-0.06	6.96
2025-08-21	MRUS	-1.04	-0.06	6.96
2025-08-22	MRUS	-1.04	-0.06	6.88
2025-08-25	MRUS	-1.15	6.47	6.88
2025-08-26	MRUS	-1.15	6.47	6.88
2025-08-27	MRUS	-1.15	6.47	6.52
2025-08-28	MRUS	-1.15	6.47	6.52
2025-08-29	MRUS	-1.15	6.47	6.52
2025-09-02	MRUS	-1.15	6.42	6.52
2025-09-03	MRUS	-1.15	6.42	6.52
2025-09-04	MRUS	-1.15	6.42	6.52
2025-09-05	MRUS	-1.15	6.42	6.52
2025-09-08	MRUS	-1.15	6.40	6.53
2025-09-09	MRUS	-1.12	6.40	6.53
2025-09-10	MRUS	-1.12	6.40	6.53
2025-09-11	MRUS	-1.12	6.40	6.41
2025-09-12	MRUS	-1.12	6.40	6.41
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-2.23

Avg. EPS Est. Current Quarter

-1.32

Avg. EPS Est. Next Quarter

-1.24

Insider Transactions

-1.12

Institutional Transactions

6.4

Beta

1.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

-0.6

Max Drawdown 5-Year %

-60.4

Target Price

92.75

P/E

Forward P/E

PEG

P/S

93.59

P/B

6.25

P/Free Cash Flow

EPS

-5.54

Average EPS Est. Cur. Y

-5.79

EPS Next Y. (Est.)

-4.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-685.64

Relative Volume

1.88

Return on Equity vs Sector %

-70.7

Return on Equity vs Industry %

-57.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

-18.2

Merus N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

stock quote shares MRUS – Merus N.V Stock Price stock today

news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch MRUS – Merus N.V yahoo finance google finance

stock history MRUS – Merus N.V invest stock market

stock prices MRUS premarket after hours

ticker MRUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y